GlassScriptPhysician profile
Deborah F Shultz
NPI 1154341014
$3,880.09
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,333 · 2020: $1,128 · 2021: $1,354 · 2022: $64.44.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $890.12 | 2019-2022 | |
| Amgen INC. | $374.16 | 2019-2021 | |
| Glaxosmithkline, LLC. | $285.76 | 2019-2021 | |
| Merz North America, INC. | $274.18 | 2021 | |
| Abbvie INC. | $266.65 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $249.31 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $229.75 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $215.03 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $178.04 | 2019-2022 | |
| Astellas Pharma US INC | $110.87 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $99.85 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $86.40 | 2021 | |
| Novo Nordisk INC | $84.52 | 2019-2021 | |
| Amarin Pharma, INC. | $70.92 | 2019-2020 | |
| Pfizer INC. | $60.83 | 2019-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $50.69 | 2020-2021 | |
| Allergan, INC. | $44.17 | 2019-2020 | |
| Aytu Biopharma, INC. | $41.72 | 2019 | |
| Abbott Laboratories | $36.11 | 2021 | |
| Lilly USA, LLC | $29.53 | 2019-2020 | |
| Eisai INC. | $24.50 | 2020 | |
| Dexcom, INC. | $21.88 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.50 | 2021 | |
| Medtronic, INC. | $20.75 | 2021 | |
| Horizon Therapeutics Plc | $20.52 | 2020 | |
| Sanofi-Aventis U.S. LLC | $18.80 | 2019 | |
| Clarus Therapeutics INC. | $15.53 | 2021 | |
| Arbor Pharmaceuticals, INC. | $15.27 | 2020 | |
| Sunovion Pharmaceuticals INC. | $15.09 | 2021 | |
| Antares Pharma, INC. | $14.48 | 2019 | |
| Genentech USA, INC. | $13.16 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Shultz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.